Ana de Barros, PhD, managing science editor —

The CHDI Foundation, a privately-funded nonprofit research organization dedicated to fighting Huntington’s disease, has awarded a research grant to a team of scientists from the University of Rochester Medical Center (URMC) to study the role of specific cells in the development of the disease. Dr. Steve Goldman, MD, PhD, co-director…

Teva Pharmaceutical presented encouraging top-line data from PRIDE-HD, a Phase 2 clinical trial evaluating the impact of pridopidine, an oral medication, on motor impairment in patients with Huntington’s disease (HD). Teva is now preparing for a larger clinical study in Huntington’s. The presentation took place at the 9th European…

Voyager Therapeutics has partnered with the CHDI Foundation to advance its VY-HTT01 gene-silencing therapy for Huntington’s disease (HD). The research alliance with CHDI builds upon an earlier partnership between CHDI and Sanofi Genzyme and includes financial support from CHDI to help in the preparation and filing of an FDA…

Vaccinex‘s VX15, a novel clinical stage monoclonal antibody for Huntington’s disease (HD) treatment, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). VX15 blocks the activity of semaphorin 4D (SEMA4D), a molecule that is thought to promote chronic inflammatory responses in the brain. “We are very pleased…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to WAVE Life Sciences‘ lead candidate WVE-120101, which is being developed for the treatment of Huntington’s disease (HD). “Each potential new therapy for Huntington’s disease gives fresh hope to the more than 30,000 Americans symptomatic with HD and…

Teva Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) answering the pharmaceutical’s New Drug Application (NDA) for SD-809 (deutetrabenazine) tablets, for the treatment of chorea associated with Huntington’s disease (HD), a condition reported by nearly 90 percent of all Huntington’s…

During the 68th American Academy of Neurology (AAN) meeting in Vancouver, Teva Pharmaceutical Industries Ltd. presented new results from its Phase III First-HD clinical trial evaluating the efficacy, safety and tolerability of SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington’s disease (HD), a…

A professor at Washington University in St. Louis, Missouri, has been awarded two grants from the National Institutes of Health (NIH) totaling over $4.5 million to study Huntington’s disease (HD) and the causes behind this devastating disease. The recipient of the grants is Rohit V. Pappu, the Edwin H. Murty Professor…

The Weill Family Foundation and Joan and Sanford I. “Sandy” Weill have donated $185,000,000 to the University of California, San Francisco, to establish the UCSF Weill Institute for Neurosciences in an effort to expedite the development of new therapies for brain and nervous system diseases, including Huntington’s disease and Alzheimer’s…

Powerful artificial lights, known as Lumie lamps, are being donated to neurologists at Cambridge University’s School of Clinical Medicine for a research project aimed at improving the quality of life for people with Huntington’s disease (HD). Bright light has been shown to have a strong impact in people’s levels of alertness, mood ,and…